Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence.
The aims of the present study were to assess changes in psychopathology and quality of life after withdrawal treatment in participants with benzodiazepine dependence that was in most cases complicated by harmful and hazardous alcohol use or high benzodiazepine doses. Seventy-six participants with benzodiazepine dependence (DSM-III-R) who participated in a randomized clinical trial of two different gradual withdrawal treatment approaches were initially assessed by Symptom Checklist-90 (SCL-90), visual analogue scales (VASs), and the Health-Related Quality of Life battery (HRQOL). The assessments were repeated after treatment ended and again after a follow-up averaging 11 months. During the study, all measurements for the participants with clinically significant (over 50%) benzodiazepine-dose decreases improved more than those for the participants with smaller decreases, and differences in the HRQOL energy/vitality, home management, and life satisfaction scores were significant. Our data indicate that in participants with complicated benzodiazepine dependence, clinically significant dose decreases are associated with improvements in their self-rated quality of life.
Vorma
Helena
H
A-clinic Foundation, Helsinki, Finland. helena.vorma@hus.fi
Naukkarinen
Hannu
H
Sarna
Seppo
S
Kuoppasalmi
Kimmo
K
D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage*; D001569:Benzodiazepines / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011594:Psychometrics; D011788:Quality of Life; D013375:Substance Withdrawal Syndrome / Q000534:rehabilitation; D019966:Substance-Related Disorders / Q000534:rehabilitation* / Q000628:therapy; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines